Thursday 4 June 2020 ,
Thursday 4 June 2020 ,
Latest News
  • Killing of 26 Bangladeshis: 'Mastermind' killed in drone attack
  • Passenger shortage forces Biman to cancel flights
  • 5 die in Chandpur hospital isolation ward in 24hr
  • Sell TCB goods at Upazila, municipality levels: HC
  • Bangladesh records 2695 coronavirus cases, 37 deaths in 24 hrs
  • Coronavirus Hotline Numbers: 01944333222, 16263, 333; website: www.corona.gov.bd
25 April, 2019 00:00 00 AM
Print

Beximco gets US FDA nod for Cyproheptadine

Staff Reporter, Dhaka
Beximco gets US FDA nod for Cyproheptadine

Beximco Pharma-ceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, yesterday announced that it has received US Food and Drug Administration (FDA) approval for anti-allergy drug Cyproheptadine Hydrochloride Tablet (4 mg).

Cyproheptadine is a generic equivalent to Periactin®Tablets (4 mg) from Merck and Company, Inc. It is an antihistamine used to relieve allergy symptoms such as hives, watery eyes, sneezing and itchy eyes or nose, said a press release.

In August 2016, Beximco Pharma became the first Bangladeshi pharmaceutical company to export medicine to the US market, following the approval of its oral solid dosage facility by the US FDA in June 2015. Cyproheptadine is now Beximco’s seventh Abbreviated New Drug Application (ANDA) approved for the US market, said the release.

Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said, “Cyproheptadine is our seventh product approved for the US market, and with our recent acquisition of eight ANDAs from Sandoz, our US portfolio now stands at 15 products. This approval gives us further confidence that our strategic focus and growing pipeline will strengthen our presence in the world’s largest pharma market.”

Beximco Pharma, leading exporter of pharmaceuticals in Bangladesh, currently has a global footprint in more than 50 countries and has been accredited by leading global regulatory authorities including the US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).

 

Comments

Most Viewed
Digital Edition
Archive
SunMonTueWedThuFri Sat
010203040506
07080910111213
14151617181920
21222324252627
282930

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting